Veradermics is trading 4.1% up at $115.95, extending a volatile pattern seen over the past week characterized by multiple ±5% swings.
- There is no fresh company-specific news or analyst action dated July 28, 2026; the move appears to be follow-through from recent biotech strength and prior positive trial headlines.
- The stock's advance occurs despite broader weakness across the biotech sector today.
- Shares continue to experience high volatility following recent positive clinical developments.